The article discusses the development of first Chinese-made biologics slated for human trials in Western countries. The author talks about the move of several drug makers to manufacturer biologic medicines in China which include Immutep and TaiMed Biologics. Also tackled is the increasing number of partnerships with Chinese companies for all stages of drug development.